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Abstract
Background:Cardiovascular diseases could be preventable; as a result, understanding
the risk factors was regarded as the major priority for healthcare providers.
Objective: The main objective of this research was to achieve a deeper insight into the
effect of long-term use of low-dose oral contraceptive pills (OCP) on the risk factors of
cardiovascular diseases.
Materials and Methods: This research was a retrospective cohort conducted (historical
and prospectively) conducted on 100 women with normal menstrual cycles aged 15 to
35 yr, who were referred to the healthcare centers in Yazd, Iran. The participants were
categorized into two groups: The OCP group was consuming the pills for 0-3, 4-23, and
24-36 months, and the non-OCP group. Participants were followed up for a minimum
of 3 months and a maximum of six months.
Results: The highest level of low-density lipoprotein (LDL), homocysteine, cholesterol,
triglyceride levels, and systolic blood pressure was observed in the OCP group in
the duration of 24 to 36 months. The Tukey’s test demonstrated that there were
comprehensible differences in the LDL (p = 0.01), cholesterol (p = 0.01), triglyceride (p
< 0.001), and homocysteine levels (p < 0.001), also systolic blood pressure (p = 0.04).
Conclusion: It was realized that the long-term consumption of low-dose OCP can
augment the incidence of some risk factors (systolic blood pressure, homocysteine
levels, cholesterol, LDL-c, and triglyceride) and lead to developing cardiovascular
diseases amongst the healthy women.
Key words: Birth control pills, Homocysteine, Nitric oxide, Dyslipidemias, Coronary
artery diseases.
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1. Introduction
Cardiovascular diseases are predicted to remain
as the most significant contributing factor for mor-
tality (26% of total deaths) until 2020 in all over
the world. Furthermore, they are supposed to be
the leading cause of mortality in Iran (1). Women in
reproductive age are less prone to cardiovascular
diseases compared to men of the same age (2).
Although OCPs have been used worldwide as
the most popular method to prevent pregnancy
for more than half a century (2, 3), researchers
have demonstrated that there is a relationship
between combined hormonal OCPs and hyperten-
sion (2, 4). Hyperhomocysteine increased plasma
homocysteine (HCY) concentration (5), so it has
been reported as a cardiovascular disease risk
factor over the last decade (6, 7). The HCY level
in premenopausal women is 20% lower than in
men, however fasting HCY level increases after
menopause and reaches the level in men (8,
9).
HCY is a sulfur-contained amino acid and as a
by-product of methionine breakdown (10) prevents
the normal function of nitric oxide (NO) resulting
from the autoxidation process. It can, therefore,
cause endothelial dysfunction (11). NO is produced
in the endothelium by L-arginine synthesis (11)
and can cause vasodilatation, -preventing platelet
accumulation- and migration (12, 13). In a study it
was shown that a decrease in NO may lead to
diseases like atherosclerosis, cardiac disease, and
hypertension (14).
Various studies have demonstrated that female
gonadal steroids may affect NO and HCY (12, 13).
However, because of the contradictory results,
it is still unclear whether an oral contraceptive
pill (OCP) is related to changes in plasma HCY
levels (15, 16) or not. Nowadays, low-dose pills
containing 0.15 mg of levonorgestrel and 0.03
mg of ethinylestradiol (16) are considered as the
usage contraindication of the pills after the age
of 35 yr. Nevertheless, the pills were widely
administered on women who are nonsmoker and
without hypertension and migraine, which pre-
disposes them to cardiovascular disease risk (17,
18).
Furthermore, it has been reported that OCPs
can change some plasma lipids concentration
including total cholesterol, high-density lipoprotein
cholesterol (HDL-c), low-density lipoprotein choles-
terol (LDL-c), and triglyceride (15-18). Consuming
OCPs can have a negative effect on the lipid
profiles in healthy women, that is, it can increase
the triglyceride level and also decrease the high-
density lipoproteins (HDL) level (18).
Although consuming OCPs can increase car-
diovascular risk factors, there are limited reports
in this regard in the literature. Therefore, this
research is designed and conducted to investigate
the relationship between cardiovascular disease
risk factors and the consumption of low-dose OCPs
amongst healthy women in Yazd, Iran.
2. Materials and Methods
This survey was a retrospective cohort, con-
ducted on 100 married women with normal men-
strual cycles aged 15 to 35 yr referred to the
healthcare centers and also family planning clinics
including Rahmht Abad, Azadshahr, Akbari, and
Dehno Health Center in Yazd, Iran.
The sample population was followed-up in 2014
for a minimum duration of three months and a
maximum of six months and the OCP users’ blood
samples were examined for two years.
2.1. Subjects
Participants were classified into OCP and non-
OCP groups. The OCP group consisted of women
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with menstrual cycles of at least three days and a
maximum of 36 days, who used OCP (Aburaihan
Pharmaceutical Co., Iran) for 0-3, 4-23, and 36- 24
months. After taking 21 pills, they stopped taking
the pills for 7 days, then they took the next box of
pills. The non-OCP group included women referred
to the health care centers for any other reasons
and did not take any birth birth-control hormonal
preparations.
2.2. Sample size and sampling method
The significance level of 5% and the test power
of 90% were used for this study. Considering the
standard deviation of HCY level in the previous
study (SD = 3.5) (19), for achieving a minimum
difference of more than 3 units between the mean
HCY levels after amaximumof sixmonths follow-up
in both groups, according to the following formula,
50 samples per group were required:
𝑛 =






The demographic data including the age, occu-
pation, educational level, family income level, as
well as data regarding the history of pregnancy,
delivery type, number of children, smoking and
alcohol habits, history of taking medication (e.g.,
OCPs), menstrual cycle, duration of OCP usage,
and physical exercise were obtained through
a face-to-face interview. The exclusion criteria
included repeated abortion history (≥ 2 times),
thyroid dysfunction, history of heart diseases in
family before the age of 40 yr, personal history
of heart disease, diabetes, hepatic disease, renal
dysfunction, and dyslipidemia. Other exclusion cri-
teria encompassed those working with pesticides,
smoking themselves or having a partner who
smokes, drinking alcohol, history of anemia, taking
vitamin supplements such as folic acid, vitamins
B6 and B12 during the last year, receiving a
blood transfusion, and being pregnant since the
last year. The essential information was gathered
through face-to-face interviews and recorded on a
checklist.
Also, a literature survey was done to determine
the factors influencing lipid profiles, HCY, and NO
levels (9-18).
2.4. Procedures
After consulting specialists, some factors influ-
encing blood biochemical parameters were deter-
mined and recorded and ultimately prepared as
a checklist validated by authorities. Based on this
checklist, the candidates who were not meet-
ing the exclusion criteria were included in the
study. The participants were categorized into four
groups. The first group had not consumed those
pills or using any other hormonal method to
prevent pregnancy. Groups 2, 3, and 4, on the
other hand, had consumed LD tablets for a time
period of 3, 4-23, and 24-36 months, respec-
tively.
The participants were followed-up for aminimum
duration of three months and a maximum of six
months. After that, their weight, blood pressure,
body mass index (BMI) (manufactured by OMRON
health care BF511, China), and waist-hip ratio (WHR)
were measured. In the end, the venous blood
samples were taken from the groups (OCP and
non-OCP groups) and were sent to the central
laboratory in Yazd to analyze the biochemical
parameters using the standard techniques (2, 17,
20-23).
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2.5. The conditions and methods of
blood biochemical parameter mea-
surements
10cc blood sample was taken from each par-
ticipants between 9 and 11 am to minimize the
chemical changes. 4 ml was put into EDTA tubes,
and 6 ml in the sodium citrate tubes being kept in
the ice throughout the preparation process, during
the time of the sampling phase until the samples
were sent to the central laboratory for analyzing
the parameters. Total cholesterol, triglyceride, HDL-
c, and LDL-c levels were measured. The following
parameters were calculated using auto Analyzer
(Hitachi, Japan) and commercial kits, manufactured
by Bionic corporation (confirmed by the Iran Health
Reference Laboratory): triglyceride levels in serum
by using the enzymatic method (lipase for convert-
ing triglyceride to glycerol), cholesterol levels by
using the enzymatic cholesterol esterase (lipase
for converting triglyceride to glycerol), and HDL-c
by using the enzymatic precipitation method. LDL-
c was also calculated using the Friedwald formula
(24).
HCY levels were determined (coefficient of
variation ≤ 5%) via the enzymatic and photomet-
ric method using the HCY kit manufactured by
Diazyme (Roche subsidiary company, USA) and
Auto Analyzer BT3000 (Biotechnics, Italy). The
NO levels were determined using a photometric
method and also Greiss reaction. A micropipette
reader (having CV < 5%), a kit manufactured by
Iran Sib Bio, and an ELISA microplate reader 3200
FaxStat (Awareness Technologies, USA) were used
in this work.
2.6. Ethical consideration
This study was approved by Shahid Sadoughi
University of Medical Sciences Ethics Committee,
Yazd, Iran (Code: IR.SSU.SPH.REC.1394.69). Written
informed consent was obtained from all partici-
pants in this study.
2.7. Data analysis
The collected data were analyzed using the
Statistical Package for the Social Sciences software
(SPSS, version 16, SPSS Inc, Chicago, Illinois, USA),
the descriptive tests, Chi-square test, indepen-
dent t-test, Tukey’s test, and ANOVA test with
a significance level of 0.05. In conclusion, the
results were attained by comparing the participants
consuming the pills with those using non-hormonal
birth control methods.
3. Results
In this study, 100 women aged 15-35-yr-old
were investigated. The basic characteristics of the
participants are displayed in Table I. In this study,
two groups were matched for age (Table I). The
women consuming the pills for the least amount of
time had the highest rate of pregnancy.
According to the results, a majority of partici-
pants in the OCP group were housewives that is
88.8%, 94.4%, and 91.3% of those exposed to the
pills for 3, 4-23, and 24-36 months, respectively.
Moreover, regarding the education level of the
participants, in the groups exposed to the pills for
3 and 24-36 months, a majority of the participants
had primary school education degree or were
illiterate. On the contrary, in the non-OCP group,
most of the participants were housewives with a
university degree (Table I).
Based on our findings, there were no
comprehensible statistical differences regarding
job (p = 0.525), educational level (p =
0.636), and hourly physical exercises in a
week (p = 0.830). Although there was no
significant difference statistically between
the two groups, there was a comprehensible
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statistical association between the groups
concerning the monthly family income level (p
= 0.011).
Anthropometric features and the participants’
blood pressure measurements are shown in Table
II. Using ANOVA test, no statistically significant
differences were found in the mean values of BMI,
WHR, and diastolic blood pressure amongst the
groups regarding the duration of the consumption
of the pills (p ≥ 0.05), while there were compre-
hensible differences in the systolic blood pres-
sure amongst the groups regarding the pills-usage
duration. Tukey’s test proved that the maximum
mean systolic blood pressure was seen amongst
the women consuming the pills for 4-23 and 24-36
months (p = 0.05).
The average incidence rates of risk factors for
increasing cardiovascular diseases amongst the
participants are displayed in Table III. There were
no remarkable differences in the mean values
of the NO and HDL levels amongst the groups
regarding the duration of the consumption of LD
contraceptive pills according to the ANOVA test.
However, there were comprehensible differences
in the mean values of LDL, HCY, cholesterol, and
triglyceride levels between the groups due to
the difference in the duration of the consump-
tion of LD contraceptive pills statistically. Tukey’s
test proved that the mean values of LDL (p =
0.02), cholesterol (p = 0.01), and triglyceride (p
< 0.001) levels amongst the users of the pills
for 24-36 months and the mean value of HCY
level among the users for 4-23 and 24-36 months
were higher than the mean values of those levels
amongst the other corresponding person (p <
0.001).
Table I. The basic participants’ characteristics (n = 100) based on the duration of the consumption of LD contraceptive pills
Variables The time of consuming LD contraceptive pills P-value
Not consuming
the pills
3 Months 4-23 Months 24-36 Months
The number of participants 50 9 18 23
Age* 30.06 ± 4.06 31.11 ± 3.55 27.55 ± 4.46 31.73 ± 2.98
0.322a
Job**
Housekeeper 43 (86) 8 (88.8) 17 (94.4) 21 (91.3)





9 (18) 4 (44.4) 3 (16.7) 7 (30.5)
Middle school 11 (22) 0 (0.0) 5 (27.7) 5 (21.7)
Diploma 14 (28) 4 (44.4) 4 (22.3) 6 (26.1)
Upper diploma 16 (32) 1 (11.2) 6 (33.3) 5 (21.7)
0.636b
The numbers of pregnancy* 2.08 ± 0.98 2.33 ± 0.86 2.22 ± 1.06 2.26 ± 0.54 0.201a
Doing physical exercises**
Never 31 (62) 6 (66.7) 10 (55.5) 12 (52.2)
Less than 2 hr per week 12 (24) 0 (0.0) 5 (27.8) 9 (39.2)
≥ 3 hr per week 7 (14) 3 (33.3) 3 (16.7) 2 (8.6)
0.830b
Income per month∗∗
< 5,000,000 R 1 (2) 2 (22.2) 3 (16.6) 3 (13.1)
5,000,000-10,000,000 R 33 (66) 6 (66.6) 11 (61.2) 18 (78.2)
> 10,000,000R 16 (32) 1 (11.2) 4 (22.2) 2 (8.7)
0.011b
*Data presented as n (%), ** Data presented as Mean ± SD
𝑎 Independent student’s t-test; 𝑏 ANOVA test
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Table II. The mean values and SD of anthropometric characteristic indexes and participants’ blood pressure measurements in




The duration of consuming LD
contraceptive pills (month)
Numbers Mean ± SD P-value*
Not consuming the pills 50 25.35 ± 4.85
3 months 9 26.66 ± 3.87
4-23 months 18 24.78 ± 4.67BMI(Kg/m
2)
24-36 months 23 26.74 ± 3.19
0.42
Not consuming the pills 50 0.85 ± 0.07
3 months 9 0.84 ± 0.05
4-23 months 18 0.83 ± 0.07WHR
24-36 months 23 0.85 ± 0.06
0.85
Not consuming the pills 50 105.22 ± 10.80
3 months 9 109.33 ± 10.46
4-23 months 18 102.44 ± 6.32Systolic blood pressure(mmHg)
24-36 months 23 110.73 ± 10.85
0.04
Not consuming the pills 50 71.04 ± 7.07
3 months 9 74.00 ± 8.29
4-23 months 18 71.11 ± 5.17Diastolic blood pressure(mmHg)
24-36 months 23 74.39 ± 8.28
0.23
*ANOVA test
BMI: Body mass index; WHR: Waist-hip ratio
Table III. The mean and SD concerning the risk factors for increasing cardiovascular diseases amongst the users of the pills
regarding the duration of the consumption of the pills
Risk factors The duration of the consumption of
the pills
Numbers Mean ± SD P-value*
Not consuming the pills 50 3.28 ± 1.61
3 months 9 3.25 ± 0.96
4-23 months 18 2.83 ± 1.38
Homocysteine levels
(µmol/l)
24-36 months 23 4.87 ± 2.91
<0.001
Not consuming the pills 50 159.74 ± 30.25
3 months 9 168.11 ± 25.12
4-23 months 18 180.16 ± 39.66
Cholesterol (mg/dl)
24-36 months 23 186.04 ± 41.51
0.01
Not consuming the pills 50 84.84 ± 24.70
3 months 9 91.02 ± 22.68
4-23 months 18 102.51 ± 30.15
LDL-c (mg/dl)
24-36 months 23 104.64 ± 33.88
0.01
Not consuming the pills 50 93.60 ± 44.01
3 months 9 101.00 ± 38.69
4-23 months 18 125.22 ± 44.32
Triglyceride (mg/dl)
24-36 months 23 144.69 ± 49.65
<0.001
Not consuming the pills 50 56.18 ± 8.91
3 months 9 56.88 ± 10.31
4-23 months 18 55.16 ± 7.01
HDL-c (mg/dl)
24-36 months 23 57.30 ± 8.90
0.88
Not consuming the pills 50 162.65 ± 90.91
3 months 9 139.14 ± 80.47
4-23 months 18 184.45 ± 95.85
Nitric oxide (µM)
24-36 months 23 195.45 ± 88.42
0.31
*ANOVA test
LDL-c: Low-density lipoproteins cholesterol; HDL-c: High-density lipoproteins cholesterol
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4. Discussion
The present study revealed that there was a
relationship between the duration of the consump-
tion of the pills and the incidence of some risk
factors for increasing cardiovascular diseases like
HCY, cholesterol, triglyceride, and LDL-c levels.
According to the results, there were no remark-
able differences amongst the participants con-
cerning BMI, WHR, and diastolic blood pressure,
while there was a significant difference in the
systolic blood pressure amongst the groups. A
study carried out by Emokpae indicated that there
was a comprehensible difference in the increased
blood pressure amongst the long-term users of
those pills (25). This finding was compatible with
our results. However, other studies accomplished
in the literature expressed that there were no
specific associations between the consumption
of the pills, weight gain (26), and the systolic
and diastolic blood pressures (25-28). Although
weight gain has been reported as a side effect
of OCPs, there is a still lack of evidence sup-
porting this notion (23). The published studies in
this regard also suggest that there is no rela-
tionship between gaining weight and long-term
usage of the pills. For example, Pelkman and
coworkers demonstrated that consuming the pills
had no influence on nutritional intake and energy
consumption and did not lead to weight gain
(29).
The present study indicated that there was a
comprehensible difference in the mean value of
the plasma level of HCY due to the difference
in the duration of the pill consumption. A study
carried out by Fallah and colleagues on 100women
with/without a history of consuming the pills in
Tehran, Iran, showed a result compatible with ours
(12).
The results proved that although the mean
values of NO and HDL-c levels among the women
using the pills for the longest period were high,
there were no significant differences in comparison
with the other groups in this regard. According
to other findings, the mean values of triglyceride,
cholesterol, and LDL-c levels among the women
consuming the pills for the longest time were
high, which in this finding was comprehensible
amongst the users of the pills statistically. More-
over, the study accomplished by Emokpae and
colleagues to investigate the influence of long-
term usage of the pills on lipid profiles showed
results compatible with our results (25). Contrasting
to this study, a study by Guazzelli to investigate
lipid profiles revealed that the duration of the
pill consumption made no statistically significant
changes in this regard (30). Dissimilar to the
conducted studies, examining the influence of
OCPs for a short period of time, investigating the
effects on women attending only one public health
clinic, and also considering no difference between
the prescribed pills, the current study has some
strengths as follows: only LD contraceptive pills
were used for a long time and they were given
to the women who attended several public health
clinics.
There were also some limitations in this study.
First, the limitation of costs for this project due
to which the study was conducted on a rela-
tively small population. Therefore, some relation-
ships were not detected due to the low sam-
ple size. Second, the study was performed in
a limited time so that only one blood sample
was taken from each participant regardless of
the follicular and luteal phase of the menstrual
cycle.
5. Conclusion
The results proposed that there was a sta-
tistically significant association concerning the
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incidence rate of risk factors for increasing car-
diovascular diseases between the women who
never used LD contraceptive pills and the coun-
terparts consuming the pills for a long time.
Hence, it can be concluded that consuming
LD contraceptive pills containing low hormones
for a long time may be accompanied by an
increased risk of developing cardiovascular dis-
eases. Therefore, given the significance of this
obstacle, it is recommended that the obtained
results of this study should be taken into account
by the healthcare providers while prescribing the
pills.
Acknowledgments
The authors thank the faculty members of the
Faculty of Health, Shahid Sadoughy University of
Medical Sciences. This study was funded by the
Vice Chancellor for Research and Technology of
Shahid Sadoughi University of Medical Sciences,
Yazd, Iran.
Conflict of Interests
The authors declare that there is no conflicts of
interests.
References
[1] Kazemy T, Sharifzadeh Gh. Ten-year changes in mor-
tality and risk factors in acute myocardial infarction in
Birjand (1994-2003). Horizon Med Sci 2004; 10: 38–
42. (in Persian)
[2] Robbins CL, Farr SL, Zapata LB, D’Angelo DV,
Callaghan WM. Postpartum contraceptive use
among women with a recent preterm birth. Am J
Obstet Gynecol 2015; 213: 508.e1–e9
[3] Alonso de Lecinana M, Egido J. Estrogens as neu-
roprotectants against ischemic stroke. Cerebrovasc
Dis 2006; 21 (Suppl.2): 48–53.
[4] Ribeiro CCM, Shimo AKK, Lopes MHBM, Lamas
JLT. Effects of different hormonal contraceptives in
women’s blood pressure values. Rev Bras Enferm
2018; 71 (suppl.3): 1453–1459.
[5] Sbarouni E, Kyriakides ZS, Kremastinos DT. The
effect of hormone replacement therapy and simvas-
tatin on plasma homocysteine. J Womens Health
(Larchmt) 2005; 14: 154–158.
[6] Gupta M, Sharma P, Garg G, Kaur K, Bedi GK, Vij
A. Plasma homocysteine: an independent or an
interactive risk factor for coronary artery disease.
Clin Chim Acta 2005; 352: 121–125.
[7] Vasan RS, Beiser A, D’Agostino RB, Levy D, Selhub
J, Jacques PF, et al. Plasma homocysteine and risk
for congestive heart failure in adults without prior
myocardial infarction. JAMA 2003; 289: 1251–1257.
[8] Kannel WB. Overview of hemostatic factors involved
in atherosclerotic cardiovascular disease. Lipids
2005; 40: 1215–1220.
[9] Serapinas D, Boreikaite E, Bartkeviciute A, Bandze-
viciene R, Silkunas M, Bartkeviciene D. The impor-
tance of folate, vitamins B6 and B12 for the lowering
of homocysteine concentrations for patients with
recurrent pregnancy loss and MTHFR mutations.
Reprod Toxicol 2017; 72: 159–163.
[10] Ardawi MS, Rouzi AA, Qari MH, Dahlawi FM, Al-
Raddadi RM. Influence of age, sex, folate and vitamin
B12 status on plasma homocysteine in Saudis. Saudi
Med J 2002; 23: 959–968.
[11] Mirzaei N, Dehpour AR. Investigation of homocystein
plasma level in cholestatic rat and its effect on nitric
oxide secretion in liver. Sci J Hamadan Univ Med Sci
2005; 12: 25–34.
Page 848 https://doi.org/10.18502/ijrm.v17i10.5496
International Journal of Reproductive BioMedicine Effects of low-dose contraceptive pills on risk factors of cardiovascular diseases
[12] Merki-Feld GS, Imthurn B, Keller PJ. Effects of two
oral contraceptives on plasma levels of nitric oxide,
homocysteine, and lipid metabolism. Metabolism
2002; 51: 1216–1221.
[13] Merki-Feld GS, Imthurn B, Keller PJ. Effects of two
oral contraceptives on plasma levels of nitric oxide,
homocysteine, and lipid metabolism. Metabolism
2002; 51: 1216–1221.
[14] Mirershadi F, Faghihi M, Dehpour AR. Effect of
endogenous nitric oxide on cardiac ischemic pre-
conditioning in rat. Repository of Research and
Investigative Information Hormozgan University of
Medical Sciences 2009; 14: 13–21. (in Persian)
[15] Lussana F, Zighetti M, Bucciarelli P, Cugno M, Catta-
neo M. Blood levels of homocysteine, folate, vitamin
B6 and B12 in women using oral contraceptives
compared to non-users. Thromb Res 2003; 112: 37–
41.
[16] Rosendaal FR, Helmerhorst FM, Vandenbroucke
JP. Female hormones and thrombosis. Arterioscler
Thromb Vasc Biol 2002; 22: 201–210.
[17] Akbarzadeh M, SHarifi N. Comparison of cardiovas-
cular disease in women with OCP use and without
OCP use in hospitals of Shiraz University of Medical
Sciences. Iran J Nurs Res 2013; 8: 19–28.
[18] Tuchman E.Women’s injection drug practices in their
own words: a qualitative study. Harm Reduct J 2015;
12: 6.
[19] Fallah S, Nouroozi V, Seifi M, Samadikuchaksaraei A,
Aghdashi EM. Influence of oral contraceptive pills on
homocysteine and nitric oxide levels: As risk factors
for cardiovascular disease. J Clin Lab Anal 2012; 26:
120–123.
[20] Kumar A, Palfrey HA, Pathak R, Kadowitz PJ, Gettys
TW, Murthy SN. The metabolism and significance of
homocysteine in nutrition and health. Nutr Metab
(Lond) 2017; 14: 78.
[21] Eslami A, Lotfaliany M, Akbarpour S, Azizi F,
Hadaegh F. Trend of cardiovascular risk factors in
the older Iranian population: 2002–2014. Geriatr
Gerontol Int 2018; 18: 130–137.
[22] Esmaillzadeh A, Mirmiran P, Azizi F. Waist-to-hip ratio
is a better screening measure for cardiovascular
risk factors than other anthropometric indicators in
Tehranian adult men. Int J Obes Relat Metab Disord
2004; 28: 1325–1332.
[23] Tohidi M, Assadi M, Dehghani Z, Vahdat K, Emami
SR, Nabipour I. High sensitive C-reactive protein and
ischemic heart disease, a population-based study.
Iran South Med J 2012; 15: 253–262.
[24] Saw SM, Yuan JM, Ong CN, Arakawa K, Lee HP,
Coetzee GA, et al. Genetic, dietary, and other
lifestyle determinants of plasma homocysteine con-
centrations in middle-aged and older Chinese men
and women in Singapore. Am J Clin Nutr 2001; 73:
232–239.
[25] Emokpae MA, Uadia PO, Osadolor HB. Effect of
duration of use of hormonal contraceptive pills on
total lipid and lipoproteins in Nigerian women. Int J
Pharm Biol Sci 2010; 1: 1–5.
[26] Grossman D, Fuentes L. Over-the-counter access
to oral contraceptives as a reproductive healthcare
strategy. Curr Opin Obstet Gynecol 2013; 25: 500–
505.
[27] Azizi F, Ainy E, Mirmiran P, Habibian S. Contraceptive
methods and risk factors of cardiovascular diseases
in Tehranian women: Tehran Lipid and Glucose
Study. Eur J Contracept Reprod Health Care 2002;
7: 1–6.
[28] Lech MM, Ostrowska L. Effects of low-dose OCs on
weight in women with central European nutritional
habits and lifestyle. Contraception 2002; 66: 159–
162.
https://doi.org/10.18502/ijrm.v17i10.5496 Page 849
International Journal of Reproductive BioMedicine Momeni et al.
[29] Pelkman CL, ChowM, Heinbach RA, Rolls BJ. Short -
term effects of a progestational contraceptive drug
on food intake, resting energy expenditure, and
body weight in young women. Am J Clin Nutr 2001;
73: 19–26.
[30] Guazzelli CA, Lindsey PC, de Araújo FF, Barbieri M,
Petta CA, Aldrighi JM. Evaluation of lipid profile in
adolescents during long-term use of combined oral
hormonal contraceptives. Contraception 2005; 71:
118–121.
Page 850 https://doi.org/10.18502/ijrm.v17i10.5496
